CN1399552A - 治疗腺病毒眼感染的方法和组合物 - Google Patents
治疗腺病毒眼感染的方法和组合物 Download PDFInfo
- Publication number
- CN1399552A CN1399552A CN00816173A CN00816173A CN1399552A CN 1399552 A CN1399552 A CN 1399552A CN 00816173 A CN00816173 A CN 00816173A CN 00816173 A CN00816173 A CN 00816173A CN 1399552 A CN1399552 A CN 1399552A
- Authority
- CN
- China
- Prior art keywords
- acetyl
- pharmaceutical composition
- sialic acid
- lactose
- aminoacyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 13
- 208000001860 Eye Infections Diseases 0.000 title description 11
- 108010061514 sialic acid receptor Proteins 0.000 claims abstract description 28
- 206010023332 keratitis Diseases 0.000 claims abstract description 8
- 201000010666 keratoconjunctivitis Diseases 0.000 claims abstract description 7
- 230000001537 neural effect Effects 0.000 claims description 46
- 239000000463 material Substances 0.000 claims description 37
- 239000008101 lactose Substances 0.000 claims description 32
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 31
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 30
- -1 dextran sulfate Chemical compound 0.000 claims description 27
- 230000003612 virological effect Effects 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 20
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 20
- 229960002897 heparin Drugs 0.000 claims description 20
- 108010061952 Orosomucoid Proteins 0.000 claims description 18
- 102000012404 Orosomucoid Human genes 0.000 claims description 18
- 229920000669 heparin Polymers 0.000 claims description 18
- 208000010370 Adenoviridae Infections Diseases 0.000 claims description 17
- 206010060931 Adenovirus infection Diseases 0.000 claims description 17
- 208000011589 adenoviridae infectious disease Diseases 0.000 claims description 17
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 16
- 230000010799 Receptor Interactions Effects 0.000 claims description 15
- 125000003047 N-acetyl group Chemical group 0.000 claims description 13
- 229920002971 Heparan sulfate Polymers 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 241001597008 Nomeidae Species 0.000 claims description 11
- 210000004392 genitalia Anatomy 0.000 claims description 10
- 238000011287 therapeutic dose Methods 0.000 claims description 9
- FDJKUWYYUZCUJX-PGIATKPXSA-N N-glycoloylneuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1OC(O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-PGIATKPXSA-N 0.000 claims description 8
- 229960000633 dextran sulfate Drugs 0.000 claims description 8
- 235000000346 sugar Nutrition 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims description 6
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims description 6
- 201000006476 shipyard eye Diseases 0.000 claims description 6
- 210000002845 virion Anatomy 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 7
- 230000003993 interaction Effects 0.000 abstract description 3
- 206010001258 Adenoviral infections Diseases 0.000 abstract 2
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 241000701161 unidentified adenovirus Species 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 10
- 108010063954 Mucins Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 6
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 5
- 101710186708 Agglutinin Proteins 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- 101710146024 Horcolin Proteins 0.000 description 4
- 101710189395 Lectin Proteins 0.000 description 4
- 101710179758 Mannose-specific lectin Proteins 0.000 description 4
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 4
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 4
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 239000000910 agglutinin Substances 0.000 description 4
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940060155 neuac Drugs 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000011323 eye infectious disease Diseases 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010048461 Genital infection Diseases 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- 244000046101 Sophora japonica Species 0.000 description 2
- 235000010586 Sophora japonica Nutrition 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- SWWGDPUXMXYQMB-AKKDPBBWSA-N (4S,5R,6R)-3-acetyl-2,4-dihydroxy-5-(hydroxyamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound ON[C@@H]1[C@H](C(C(C(O)=O)(O)O[C@H]1[C@H](O)[C@H](O)CO)C(C)=O)O SWWGDPUXMXYQMB-AKKDPBBWSA-N 0.000 description 1
- ZUQUTHURQVDNKF-WZPXOXCRSA-N 1-[(3S,4R,5S,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethanone Chemical compound C(C)(=O)C1(O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO ZUQUTHURQVDNKF-WZPXOXCRSA-N 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000709716 Human enterovirus 70 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108010084938 adenovirus receptor Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- BQINXKOTJQCISL-GRCPKETISA-N keto-neuraminic acid Chemical compound OC(=O)C(=O)C[C@H](O)[C@@H](N)[C@@H](O)[C@H](O)[C@H](O)CO BQINXKOTJQCISL-GRCPKETISA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
Abstract
Description
Claims (21)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE99042897 | 1999-11-26 | ||
SE9904289A SE9904289D0 (sv) | 1999-11-26 | 1999-11-26 | Method and camposition for the treatment of adenovairal ocular infections |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1399552A true CN1399552A (zh) | 2003-02-26 |
CN100566722C CN100566722C (zh) | 2009-12-09 |
Family
ID=20417870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008161739A Expired - Fee Related CN100566722C (zh) | 1999-11-26 | 2000-11-23 | 治疗腺病毒眼感染的方法和组合物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7528113B2 (zh) |
EP (1) | EP1231925B1 (zh) |
JP (1) | JP4559613B2 (zh) |
CN (1) | CN100566722C (zh) |
AT (1) | ATE297211T1 (zh) |
AU (2) | AU1908601A (zh) |
DE (1) | DE60020729T2 (zh) |
HK (1) | HK1052139B (zh) |
SE (1) | SE9904289D0 (zh) |
WO (1) | WO2001037846A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102471362A (zh) * | 2009-07-07 | 2012-05-23 | 阿登诺维尔制药公司 | 用于治疗或预防流行性角膜结膜炎的新型抗病毒化合物 |
CN104586642A (zh) * | 2015-02-06 | 2015-05-06 | 武汉中科光谷绿色生物技术有限公司 | N-乙酰神经氨酸单体、n-乙酰神经氨酸水合物或n-乙酰神经氨酸盐在个人护理用品中的应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2116140A1 (en) * | 2008-05-08 | 2009-11-11 | Nestec S.A. | Sialic acid to support the immune system in the elderly |
KR101116868B1 (ko) * | 2008-10-20 | 2012-02-29 | 성균관대학교산학협력단 | 안질환의 예방 또는 치료용 조성물 |
EP2364139A2 (en) | 2008-11-10 | 2011-09-14 | Life Science Nutrition AS | Ngna compositions and methods of use |
KR20160073372A (ko) | 2013-08-28 | 2016-06-24 | 아데노비르 파마 에이비 | 다가의 시알산 유도체 |
CN108904633A (zh) * | 2018-10-19 | 2018-11-30 | 长沙浩然医疗科技有限公司 | 一种改善视力的眼膏及其制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
AU649110B2 (en) * | 1991-03-07 | 1994-05-12 | Mect Corporation | Pharmaceutical preparation |
GB2261372A (en) | 1991-11-15 | 1993-05-19 | Gregor Reid | Lactobacillus and skim milk compositions for prevention of urogenital infection |
US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
US5858698A (en) | 1994-04-21 | 1999-01-12 | University Of Alberta | Methods for detection of enteropathogenic e. coli |
AUPM623994A0 (en) * | 1994-06-15 | 1994-07-07 | Biomolecular Research Institute Limited | Antiviral dendrimers |
JP3141693B2 (ja) * | 1994-08-16 | 2001-03-05 | ダイキン工業株式会社 | シアル酸の9位をフッ素で置換したガングリオシドgm3類縁体及びその中間体 |
US5962311A (en) * | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
DE19547972A1 (de) * | 1995-12-21 | 1997-07-10 | Weropharm Gmbh | Heparin zur Prophylaxe und akuten Therapie der allergischen Konjunktivitis |
CN1211189A (zh) | 1996-02-14 | 1999-03-17 | 普罗克特和甘保尔公司 | 含衍自杜鹃花科植物的物质和乳酸菌生长因子的,用于泌尿生殖系统和肠道疾病的组合物 |
ES2127110B1 (es) | 1996-05-24 | 1999-12-01 | Univ Valladolid | Procedimiento para variar las propiedades electricas del moco ocular humano y de sustitutos para uso oftalmico. |
US5719020A (en) * | 1996-09-25 | 1998-02-17 | Oklahoma Medical Research Foundation | 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinical specimens |
WO1998048817A1 (en) | 1997-05-01 | 1998-11-05 | Cytel Corporation | Use of sialyl galactosides and related compounds as anti-angiogenic agents |
US20050201952A1 (en) * | 1998-01-29 | 2005-09-15 | Yash Sharma | Treatment and prevention of viral hepatitis infections |
WO1999067283A2 (en) * | 1998-06-24 | 1999-12-29 | University Of Dundee | Two-kinase domain mitogen- and stress-activated protein kinases and uses thereof |
AT408946B (de) | 1999-02-18 | 2002-04-25 | Immuno Ag | Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation |
-
1999
- 1999-11-26 SE SE9904289A patent/SE9904289D0/xx unknown
-
2000
- 2000-11-23 AU AU19086/01A patent/AU1908601A/en not_active Abandoned
- 2000-11-23 WO PCT/SE2000/002313 patent/WO2001037846A1/en active IP Right Grant
- 2000-11-23 AT AT00982008T patent/ATE297211T1/de not_active IP Right Cessation
- 2000-11-23 EP EP00982008A patent/EP1231925B1/en not_active Expired - Lifetime
- 2000-11-23 CN CNB008161739A patent/CN100566722C/zh not_active Expired - Fee Related
- 2000-11-23 DE DE60020729T patent/DE60020729T2/de not_active Expired - Lifetime
- 2000-11-27 JP JP2000359325A patent/JP4559613B2/ja not_active Expired - Fee Related
-
2003
- 2003-06-18 HK HK03104387.0A patent/HK1052139B/zh not_active IP Right Cessation
-
2004
- 2004-11-29 US US10/997,955 patent/US7528113B2/en not_active Expired - Fee Related
-
2007
- 2007-05-29 AU AU2007202447A patent/AU2007202447B2/en not_active Ceased
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102471362A (zh) * | 2009-07-07 | 2012-05-23 | 阿登诺维尔制药公司 | 用于治疗或预防流行性角膜结膜炎的新型抗病毒化合物 |
CN102471362B (zh) * | 2009-07-07 | 2015-02-18 | 阿登诺维尔制药公司 | 用于治疗或预防流行性角膜结膜炎的抗病毒化合物 |
CN104586642A (zh) * | 2015-02-06 | 2015-05-06 | 武汉中科光谷绿色生物技术有限公司 | N-乙酰神经氨酸单体、n-乙酰神经氨酸水合物或n-乙酰神经氨酸盐在个人护理用品中的应用 |
Also Published As
Publication number | Publication date |
---|---|
DE60020729T2 (de) | 2006-05-11 |
AU2007202447A1 (en) | 2007-06-21 |
AU2007202447B2 (en) | 2010-03-11 |
JP4559613B2 (ja) | 2010-10-13 |
AU1908601A (en) | 2001-06-04 |
JP2001151701A (ja) | 2001-06-05 |
EP1231925A1 (en) | 2002-08-21 |
EP1231925B1 (en) | 2005-06-08 |
SE9904289D0 (sv) | 1999-11-26 |
CN100566722C (zh) | 2009-12-09 |
ATE297211T1 (de) | 2005-06-15 |
US7528113B2 (en) | 2009-05-05 |
DE60020729D1 (de) | 2005-07-14 |
HK1052139B (zh) | 2010-04-23 |
US20050080041A1 (en) | 2005-04-14 |
WO2001037846A1 (en) | 2001-05-31 |
HK1052139A1 (en) | 2003-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tiwari et al. | Role of heparan sulfate in sexually transmitted infections | |
JP7244582B2 (ja) | 二重誘導体化キトサンナノ粒子、並びに生体内での遺伝子導入のためのその製造、及び使用方法 | |
KR950702834A (ko) | 글루칸 제제(novel glucan preparation) | |
CN1399552A (zh) | 治疗腺病毒眼感染的方法和组合物 | |
Lamblin et al. | Human respiratory mucins | |
KR20090079912A (ko) | 노로바이러스 백신 제제 | |
CN1195296A (zh) | 含白蛋白为有效成分的药物组合物 | |
JPH04502011A (ja) | ポリペプチド誘導体 | |
Umemura et al. | Design of a sialylglycopolymer with a chitosan backbone having efficient inhibitory activity against influenza virus infection | |
CN1227493A (zh) | 肝素或硫酸乙酰肝素与脱乙酰壳多糖结合用于预防或治疗由疱疹病毒引起的感染 | |
JP2001509492A5 (zh) | ||
JPH04502153A (ja) | マイコプラズマ ニューモニエ及びマイコプラズマホミヌスのスルファチドへの接着 | |
Ogata et al. | Chemoenzymatic synthesis of sialoglycopolypeptides as glycomimetics to block infection by avian and human influenza viruses | |
CN1290867C (zh) | 获自狭叶紫锥花的多聚糖 | |
Sakurai et al. | Different role of serum components and cytokines on alveolar macrophage activation by soluble fungal (1→ 3)-β-D-glucan | |
WO1998009981A9 (en) | Human salivary proteins and fragments thereof having alpha-glucosidase inhibitory activity | |
CN101054415A (zh) | 抗人巨细胞病毒包膜糖蛋白b的人源化单链抗体 | |
JP3271008B2 (ja) | コンドロイチン硫酸類の製造方法 | |
EP0639983A1 (en) | Antiviral agent comprising cd4 and an h2 histone | |
US11241393B2 (en) | Organosilicon carriers for use in treating infections and/or diseases caused by SARS viruses | |
US20150094255A1 (en) | Lectin Conjugates for Mucin Hydration | |
CN1185115A (zh) | 多粘菌素轭合物 | |
JPH08501803A (ja) | アミノ糖および糖蛋白、その製法、それらアミノ糖または糖蛋白を含む医薬製剤およびそれらの製剤の用途 | |
AU7328698A (en) | Improved delivery of disease modifiers | |
Singh | The existence of lipophosphoglycanlike molecules in Trichomonads |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ARDEN NORVELL PHARMACEUTICAL Free format text: FORMER OWNER: GRAN WADELL; APPLICANT Effective date: 20080801 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080801 Address after: Helsingborg Applicant after: Adenovir Pharma AB Address before: Swedish chicken Applicant before: Goran Weddle Co-applicant before: Niklas Arnberg |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1052139 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091209 Termination date: 20181123 |
|
CF01 | Termination of patent right due to non-payment of annual fee |